Pharma's Almanac | Viral Vector (2)

43 Articles Available

2 2

Gene Therapy

Slow Progress and a Shaky Start—What’s Next for Gene Therapy?

PAP-Q4-19-NI-001

Plasmids

The Pivotal Role of Plasmid DNA

PAP-Q4-19-CL-006

AAV Vector Production

Production of AAV Vectors Using Suspension Mammalian and Insect Cell Systems

PAP-Q3-19-CL-006

Capacity Expansion

Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility

PR-M07-19-NI-043

Viral Vector Collaboration

Cobra Biologics and Symbiosis Complete £4.8m Viral Vector Supply Chain Collaboration

PR-M06-19-NI-053

Viral Vectors

Research Group Developing Lentiviral Vectors for Treatment of Hemophilia

PAO-M05-19-NI-035

Viral Vector Manufacturing

Accelerating The Development of Viral Vector Manufacturing Processes

PAP-Q2-2019-CL-009

AAV and LV Vectors

Supporting AAV and Lentiviral Vector Development and Commercialization

PAP-Q2-2019-CL-005

Viral Vector Manufacturing

$1.01 Billion Viral Vector Manufacturing - Global Market Outlook 2017-2026

PR-M04-19-NI-081

QPCR

Digital Droplet PCR for Viral Vector Analysis

PAP-Q1-2019-CL-005

Viral Vectors

Preclinical to Nearly Commercial Virus and Viral Vector Manufacturing

PAP-Q1-2019-CL-020

Viral Vector Manufacturing

From Proof of Concept to Commercialization

PAP-Q4-18-CL-003

Viral Vector Manufacturing

The Future of the Viral Vector Manufacturing Market

PAO-M09-18-CL-003

Viral Vector

Flexible, Mobile, Modular: High-Containment Viral Vector Center of Excellence

PAP-Q2-18-CL-005

Capacity Expansion

Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion

PR-M03-18-NI-079

Viral Vector

Ensuring Confidence in Viral Vector Manufacturing

PAP-Q1-18-CL-012

Transient Transfection

Transient Transfection at a Large Scale for Flexibility in Clinical and Commercial Vector Manufacturing

PAP-Q3-17-CL-005

Innovation

Research Collaboration Will Focus on the Development of New CAR T-Cell Treatments

PAO-M07-17-NI-007

Investing for Successful Advancement of Viral Vector Manufacturing

PAP-Q1-17-CL-007

2 2

Viral Vector (2)

43 Articles Available

Can't find what you're looking for? Try our advanced search.

Gene Therapy

Slow Progress and a Shaky Start—What’s Next for Gene Therapy?

Plasmids

The Pivotal Role of Plasmid DNA

AAV Vector Production

Production of AAV Vectors Using Suspension Mammalian and Insect Cell Systems

Capacity Expansion

Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility

Viral Vector Collaboration

Cobra Biologics and Symbiosis Complete £4.8m Viral Vector Supply Chain Collaboration

Viral Vectors

Research Group Developing Lentiviral Vectors for Treatment of Hemophilia

Viral Vector Manufacturing

Accelerating The Development of Viral Vector Manufacturing Processes

AAV and LV Vectors

Supporting AAV and Lentiviral Vector Development and Commercialization

Viral Vector Manufacturing

$1.01 Billion Viral Vector Manufacturing - Global Market Outlook 2017-2026

QPCR

Digital Droplet PCR for Viral Vector Analysis

Viral Vectors

Preclinical to Nearly Commercial Virus and Viral Vector Manufacturing

Viral Vector Manufacturing

From Proof of Concept to Commercialization

Viral Vector Manufacturing

The Future of the Viral Vector Manufacturing Market

Viral Vector

Flexible, Mobile, Modular: High-Containment Viral Vector Center of Excellence

Capacity Expansion

Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion

Viral Vector

Ensuring Confidence in Viral Vector Manufacturing

Transient Transfection

Transient Transfection at a Large Scale for Flexibility in Clinical and Commercial Vector Manufacturing

Innovation

Research Collaboration Will Focus on the Development of New CAR T-Cell Treatments

Investing for Successful Advancement of Viral Vector Manufacturing